As Primary Axillary Hyperhidrosis becomes increasingly prevalent worldwide and is linked to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising need for safer and more effective therapies. According to DelveInsight, the pipeline for Primary Axillary Hyperhidrosis includes 5+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates. These candidates are at various stages of clinical and preclinical development, reflecting significant innovation and dedication to tackling this public health concern.
DelveInsight’s “Primary Axillary Hyperhidrosis Pipeline Insight 2025” report offers a comprehensive evaluation of the current R&D landscape. It highlights clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as a valuable resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving Primary Axillary Hyperhidrosis therapeutics market and the innovations shaping its future.
Explore the Cutting-Edge Landscape of Primary Axillary Hyperhidrosis Drug Development
During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER™ program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.
Key Takeaways from the Primary Axillary Hyperhidrosis Pipeline Report
DelveInsight’s Primary Axillary Hyperhidrosis pipeline report highlights a dynamic landscape with 5+ active companies developing 5+ therapeutic candidates for the treatment of Primary Axillary Hyperhidrosis.
In June 2024, the U.S. Food and Drug Administration (FDA) approved Sofdra™ (sofpironium bromide) topical gel, 12.45% for managing primary axillary hyperhidrosis, a condition marked by excessive underarm sweating. This approval represents the first new chemical entity in the U.S. specifically indicated for this disorder.
Leading companies in the Primary Axillary Hyperhidrosis space, including Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff GmbH & Co. KG Arzneimittel, and others, are actively developing new treatments to enhance the therapeutic landscape. Promising pipeline candidates at various stages of development include Sofpironium Bromide, DMT-410, and additional therapies.
Primary Axillary Hyperhidrosis Overview:
Primary hyperhidrosis is a rare disorder characterized by excessive sweating in localized areas, including the palms, soles, groin, or under the breasts. A common form, Primary Axillary Hyperhidrosis, specifically involves overactive underarm sweating. Although the precise cause is not fully understood, it is thought to arise from increased cholinergic sympathetic nerve activity that overstimulates the sweat glands in the underarms. The condition affects both men and women equally and usually emerges during childhood or adolescence.
Download the Primary Axillary Hyperhidrosis sample report to know in detail about the Primary Axillary Hyperhidrosis treatment market
Primary Axillary Hyperhidrosis Pipeline Analysis
The Primary Axillary Hyperhidrosis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Primary Axillary Hyperhidrosis Market.
Categorizes Primary Axillary Hyperhidrosis therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Primary Axillary Hyperhidrosis drugs under development based on:
Stage of development
Primary Axillary Hyperhidrosis Route of administration
Target receptor
Monotherapy vs. combination therapy
Primary Axillary Hyperhidrosis Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Primary Axillary Hyperhidrosis Licensing agreements
Funding and investment activities supporting future Primary Axillary Hyperhidrosis market advancement.
Unlock key insights into emerging Primary Axillary Hyperhidrosis therapies and market strategies here: https://www.delveinsight.com/report-store/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Primary Axillary Hyperhidrosis Emerging Drugs
Sofpironium Bromide – Brickell Biotech Inc.
Brickell Biotech’s leading investigational drug, Sofpironium Bromide, is a topically applied small-molecule therapy developed for Primary Axillary Hyperhidrosis. It acts as a retro-metabolically engineered anticholinergic, selectively targeting M3 acetylcholine receptors, with the potential to decrease sweat gland activity.
DMT-410 – Dermata Therapeutics LLC
Dermata Therapeutics is advancing DMT-410, a combination therapy that integrates DMT-310 with botulinum toxin, for the treatment of axillary hyperhidrosis. This therapeutic approach has shown promising results in Phase I clinical trials.
Primary Axillary Hyperhidrosis Pipeline Therapeutic Assessment
Primary Axillary Hyperhidrosis Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Primary Axillary Hyperhidrosis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Primary Axillary Hyperhidrosis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Primary Axillary Hyperhidrosis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Primary Axillary Hyperhidrosis therapies and key Primary Axillary Hyperhidrosis companies: https://www.delveinsight.com/sample-request/primary-axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Primary Axillary Hyperhidrosis Current Treatment Patterns
4. Primary Axillary Hyperhidrosis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Primary Axillary Hyperhidrosis Late-Stage Products (Phase-III)
7. Primary Axillary Hyperhidrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Axillary Hyperhidrosis Discontinued Products
13. Primary Axillary Hyperhidrosis Product Profiles
14. Primary Axillary Hyperhidrosis Key Companies
15. Primary Axillary Hyperhidrosis Key Products
16. Dormant and Discontinued Products
17. Primary Axillary Hyperhidrosis Unmet Needs
18. Primary Axillary Hyperhidrosis Future Perspectives
19. Primary Axillary Hyperhidrosis Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Primary Axillary Hyperhidrosis pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Leave a Reply